Annex 5: Acceptance Form

The Undersigned, Erlina Burhan, confirms to have read, understood and accepted the terms of the
Request for Proposals (RFP) No. RFP 044-2023, and its accompanying documents. If selected by WHO
for the work, the Undersigned undertakes, on its own behalf and on behalf of its possible partners and
Contractors, to perform RFP template in accordance with the terms of this RFP and any corresponding
contract between WHO and the Undersigned, ☐ for the following sums ☐ P for the amount(s) below and
attached Excel form.

The itemized amounts for each of the deliverables must be completed in the attached Excel form, and must
be uploaded as part of the Financial Proposal. The bidder must ensure that the amount of each Deliverable
or of the total amount is identical in the attached Excel sheet and in Annex 5 below. In case of inconsistency
between those two documents, the most favorable terms to WHO in either the Excel sheet or the Annex 5
shall prevail.

Item Cost*
Deliverable 1: The date of executed agreement 18,866 USD
Deliverable 2: After Kick-off Meeting 12,434 USD
Deliverable 3: After Finalization Workshop 4,011 USD
Deliverable 4: After Dissemination of the Guideline 4,170 USD
TOTAL PROJECT COST 39,481 USD
*UN Operational Rate of Exchange as per 15 March 2023 is IDR 15,372/1 USD

The enclosed Proposal is valid for 180 days from the date of this form (Ref. Paragraph 4.8).

Agreed and accepted, in Jakarta original copies on 10th of April, 2023

Entity Name: Yayasan Riset dan Pelatihan Respirasi Indonesia

Poli Paru Lt.2 RSUP Persahabatan

Mailing Address: Jl. Persahabatan Raya No. 01 RT 016 RW 013 Pisangan Timur, Pulo Gadung, Jakarta Timur
13230

Name and Title of Duty Dr. dr. Erlina Burhan, MSc, Sp.P(K)
Authorized Representative:

Signature:

Date: 10th of April 2023

Request for Proposals: RFP 044-2023

Annex 3: Proposal Completeness Form (Ref. Paragraphs 4.4 & 4.6)

Section Requirements Completed in full (Yes/No)

Annex 2 Confidentiality undertaking form PYes No

Annex 3 Proposal completeness form PYes No

Annex 4 Information about Bidder PYes No

Annex 5 Acceptance form PYes No

Annex 6 Self-Declaration form PYes No

4.12.2 to Technical Proposal, including Executive Summary, proposed

4.12.5 solution, approach/methodology and timeline PYes No

4.12.6 Financial Proposal PYes No

The enclosed Proposal is valid for 180 days from the date of this form (Ref. Paragraph 4.8).

Agreed and accepted, in Jakarta original copies on 10th of April, 2023

Entity Name: Yayasan Riset dan Pelatihan Respirasi Indonesia

Poli Paru Lt.2 RSUP Persahabatan

Mailing Address: Jl. Persahabatan Raya No. 01 RT 016 RW 013 Pisangan Timur, Pulo Gadung, Jakarta Timur
13230

Name and Title of Duty Dr. dr. Erlina Burhan, MSc, Sp.P(K)
Authorized Representative:

Signature:

Date: 10th of April 2023

 Technical Proposal RFP-044-2023

Executive Summary
Tuberculosis (TB) remains a significant health issue globally, with Indonesia being the
second-largest contributor. This updated guideline aims to address TB and its comorbidities, such
as HIV, diabetes, and undernutrition, by utilizing the latest evidence and summarizing existing
WHO recommendations. The target audience includes the Ministry of Health, healthcare
workers, non-medical stakeholders, patients, and their families in Indonesia.

The guideline development process follows WHO principles, including identifying priority
topics, establishing a multidisciplinary guideline development group (GDG), defining the scope
and objectives, conducting systematic evidence reviews, formulating recommendations, external
review, and finalization and approval. The GDG comprises diverse experts and representatives
from various fields related to TB and comorbidities.

This proposal outlines the methodology, objectives, process, and output for each step,
emphasizing the importance of a structured process for developing recommendations. The final
guideline will be published and disseminated to relevant stakeholders and the public. Ultimately,
the updated guideline aims to assist national TB control program managers, medical
practitioners, and policy-makers in Indonesia in making informed policy decisions to combat TB
and its comorbidities more effectively.
Background and Rationale
Tuberculosis (TB) is a major cause of illness and death globally, with Indonesia being the world's
second-largest contributor to TB. There are several health-related risk factors for TB, including
HIV, diabetes, alcohol use, smoking, and undernutrition. To combat the spread of TB and
comorbidities, it is vital to improve access to quality TB services, increase case detection, and
provide comprehensive treatment and care. In October 2022, WHO launched a Framework for
collaborative action on TB and comorbidities to enhance the response to TB and comorbidities.
The Framework provides strategies for building strong collaborations across health programs and
other stakeholders to combat TB and comorbidities, emphasizing the importance of creating
guidelines to address TB with comorbidities.

Target Audience
● Ministry of Health and Health District Office in Indonesia
● Healthcare workers in Indonesia
● Non-medical stakeholders in Indonesia
● Patients and its family

Persons Affected by the Recommendations

● Patients with TB and its comorbidities, such as TB-HIV, TB-DM, TB-Malnutrition,
TB-Tobacco, and other comorbidities

Related Guidelines
● WHO launched a Framework for collaborative action on TB and comorbidities (2022)
● WHO operational handbook on tuberculosis. Module 4: treatment - tuberculosis care and
support (2022)
● Strategi Nasional Penanggulangan Tuberkulosis di Indonesia 2020 - 2024 (2021)
● Rencana Aksi Nasional Kolaborasi TB-HIV 2020-2024 (2021)
● Konsensus Pengelolaan Tuberkulosis dan Diabetes Melitus (TB-DM) di Indonesia
(2015)
● Panduan Pelaksanaan Program Kolaborasi TB-HIV (2015)
● Petunjuk Teknis Tata Laksana Klinis Ko-Infeksi TB-HIV (2012)
● Buku Petunjuk TB-HIV untuk Petugas Kesehatan (2016)
● Petunjuk Teknis Penemuan Pasien TB‐DM di FKRTL (2015)
● Integrated care for tuberculosis (TB) and diabetes mellitus (DM) comorbidity in Asian
countries: health system challenges and opportunities. Policy brief. Vol.9 No.1. 2022
● Integrating collaborative TB and HIV services within a comprehensive package of care
for people who inject drugs: consolidated guidelines (2016)
● Guideline: Nutritional care and support for patients with tuberculosis (2013)
● Collaborative framework for care and control of tuberculosis and diabetes (2011)
Goal and objectives of the guidelines
This updated guideline aims to utilize the latest available evidence on the treatment of TB and
comorbidities to assist national TB control program managers, medical practitioners, and
policy-makers in Indonesia in making informed policy decisions.

The guideline has two primary objectives:

- to provide up-to-date recommendations based on emerging evidence on the treatment of
TB and comorbidities and
- to summarize all existing WHO recommendations on the treatment of drug-susceptible
TB along with changes made in the new guidelines.

Contributors to the guideline

● Team Leader: Dr. dr. Erlina Burhan, SpP(K), MSc
● Co-writers:
○ Dr. dr. Fathiyah Isbaniah, Sp.P(K), MPd.Ked (TB-DM)
○ Dr. dr. Raden Rara Diah Handayani, Sp.P(K) (TB-COVID 19)
○ Dr. dr. Heidy Agustin, Sp.P(K) (TB-HIV)
○ dr. Riyadi Sutarto, SpP (TB-Tobacco)
○ dr. Faiza Hatim, SpP (TB-Nutrition)
● Administrative Staff: dr. Nildza Kheirizzad

Methodology
The methodology used in this document is in line with the principles of guideline development
and stepwise instruction on the technical and procedural aspects provided by WHO Handbook of
Guideline Development 2nd Edition. The objectives of each of the steps undertaken are as
follows:

1. Identification of priority topics: The priority health topics that are being evaluated on this
guideline making process are TB and Comorbidities, such as TB HIV, TB Diabetes
Melitus, TB and Nutrition, TB and Tobacco, TB and other comorbidities (mental health,
immunocompromised, COVID-19 and other respiratory infection).

2. Establishment of a guideline development group (GDG): A multidisciplinary group of

experts is assembled, including subject matter specialists, methodologists, and
representatives of affected populations. The GDG is responsible for providing technical
input, reviewing evidence, and formulating recommendations. We select GDG from a
diverse range of expertise on every sub-topic with the composition of as follows
a. The GDG on TB and HIV will consist of the co-writer (Dr. dr. Heidy Agustin,
Sp.P(K), 2 assistant writers, the representatives from Ministry of Health TB Task
Force (1 person), Ministry of Health HIV-STI Task Force (1 person), WHO
 Indonesia (1 person), National AIDS Prevention Commission (2 persons),
Coalition of Professional Organizations HIV-AIDS (2 persons), HIV Expert Panel
(2 persons), Directorate General of Human Rights of the Ministry of Law and
Human Rights (1 person), and Indonesia AIDS Coalition (1 person).
b. For TB and Diabetes Mellitus, the GDG will consist of the co-writer (dr. Fathiyah
Isbaniah, Sp.P(K), MPd.Ked), 2 assistant writers, the representatives from
Ministry of Health TB Task Force (1 person), Ministry of Health Work Team for
Prevention and Control of Diabetes Mellitus and Metabolic Disorders (1 person),
WHO Indonesia (1 person), Indonesian Society of Endocrinology (2 persons),
Coalition of Professional Organizations TB (2 persons), Directorate General of
Customs and Excise of Ministry of Finance (1 person), and POP TB Indonesia (1
person).
c. For TB and Nutrition, the GDG will consist of the co-writer (dr. Faiza Hatim,
SpP), 2 assistant writers, the representatives from Ministry of Health TB Task
Force (1 person), Directorate General of Public Health of Ministry of Health (1
person), WHO Indonesia (1 person), Indonesia Nutrition Association (2 persons),
Association of Indonesian Internal Medicine Specialists (1 person), Indonesian
Society of Respirology (1 person), Directorate of Community Health and
Nutrition of Ministry of National Development Planning (1 person), and POP TB
Indonesia (1 person).
d. For TB and Tobacco, the GDG will consist of the co-writer (dr. Riyadi Sutarto,
SpP), 2 assistant writers, the representatives from Ministry of Health TB Task
Force (1 person), Directorate General of Health Promotion of Ministry of Health
(1 person), WHO Indonesia (1 person), National Tobacco Control Committee (2
persons), Indonesian Society of Respirology (1 person), Indonesian Pediatrician
Association (1 person), irectorate General of Customs and Excise of Ministry of
Finance (1 person), Director General of Elementary & Secondary Education of
Ministry of Education, Culture, Research, and Technology (1 person), and POP
TB Indonesia (1 person).
e. For TB and Other Comorbidities, the GDG will consist of the co-writer (Dr. dr.
Raden Rara Diah Handayani, Sp.P(K)), 2 assistant writers, the representatives
from Ministry of Health TB Task Force (1 person), COVID-19 Task Force, WHO
Indonesia (1 person), Indonesian Society of Respirology (1 person), Association
of Indonesian Internal Medicine Specialists (1 person), Indonesian Psychiatrists
Association (1 person), National Agency for Disaster Countermeasure (1 person),
and POP TB Indonesia (1 person).

3. Scoping and defining the guideline's scope and objectives: The scope, objectives, and key
questions to be addressed by the guideline are defined in collaboration with the GDG and
 other stakeholders. This ensures that the guideline is focused on relevant and important
aspects of the health issue.

4. Systematic review of evidence: A comprehensive and systematic review of the available

evidence is conducted to inform the development of recommendations. This includes
evaluating the quality of evidence, the balance of benefits and harms, and other factors
such as cost-effectiveness, feasibility, and equity.

5. Formulation of recommendations: Based on the evidence review, the GDG formulates

draft recommendations. These recommendations are developed using a structured
process, such as the GRADE (Grading of Recommendations Assessment, Development,
and Evaluation) approach, which considers the quality of evidence, the balance of
benefits and harms, values and preferences, and resource implications.

6. External review: The draft guideline undergoes external peer review by independent
experts who evaluate the quality and relevance of the recommendations. This step
ensures that the guideline is scientifically sound and that potential conflicts of interest
have been adequately addressed.

7. Finalization and approval: The GDG addresses any comments from the external review,
and the final guideline is submitted to the appropriate WHO department for review and
approval. Once approved, the guideline is published and disseminated to relevant
stakeholders.

Proposed Solutions
1. Establishment of the GDG
a. Process:
- Formal introduction of the objectives and methodology of the guideline
development and invitation for the relevant stakeholders and experts
- Initial kick-off meeting with GDG invitee
b. Output: The establishment of the GDG
2. Scoping and defining the guideline's scope and objectives
a. Process:
- Scoping a guideline includes drafting a proposed scope and priority topics
in the context of TB and comorbidities, convene the draft among the core
writing team to seek for feedback, refining the topic list, conducting a
preliminary literature search, formulating key questions in the form of
population, intervention, comparator and outcome (PICO), considering
equity and human rights, reviewing, and reconsidering the scope.
b. Output: The guideline’s scope and objectives
3. Systematic review of evidence
a. Process:
- On each GDG, 2 persons will assist the systematic reviews of the
evidence. Qualified experts will be identified early and will be invited to
identify the foreground questions in the format of PICO, list and prioritize
relevant outcomes, perform the systematic review and evidence
assessment
b. Output: Systematic review of the relevant outcomes in the topic with its relevant
evidence quality
4. Formulation of recommendations
a. Process:
- Guideline development group will discuss thoroughly the direction and
strength of the recommendation, considering factors such as quality of the
evidence, values and preferences, balance of benefits and harms, resource
implications, priority of the problem, equity and human rights,
acceptability, and feasibility
b. Output: Draft recommendations
5. External review
a. Process:
- External reviewer will examine the final guideline and detect any
omissions or inaccuracies while also offering insights on clarity, issues
specific to the setting, and the impact of implementation.
b. Output: Final draft guideline
6. Finalization and approval
a. Process:
- Revise and finalize the guideline based on inputs from external reviewer
- Workshop to disseminate the final guideline
- Submission of the final guideline
b. Output: Final guideline
Proposed Timeline

No. Activities Month 1 (May) Month 2 (June) Month 3 (July) Month 4 (August)

1 2 3 4 5 1 2 3 4 1 2 3 4 1 2 3 4 5

Kick-Off Meeting with relevant counterparts

1
to establish the Guideline Development Group

Scoping and defining guideline scope and

2
objectives

3 Systematic review of the evidence

Series of meeting between GDG with MoH

4 and technical experts to formulate the
recommendations

4a TB HIV

4b TB and Diabetes Mellitus

4c TB and Nutrition

4d TB and Tobacco
 TB and other comorbidities (mental health,
4e immunocompromised, COVID-19 and other
respiratory infection)
Core team to develop draft of National
5 Guidelines on TB and Comorbidities and
presentation slides per chapter
Workshop to finalize the National Guidelines
6 on TB and Comorbidities with external
reviewer
Core team to revise and finalize the guideline
7
draft based on the input from the workshop

Workshop to disseminate National Guideline

8
on TB and Comorbidities

Submission of the final draft of National

9
Guideline on TB and Comorbidities
Request for Proposals: RFP 044-2023

Annex 4: Information about Bidder

1. Company Information
1.1. Corporate information and service provided
The challenge of eradicating tuberulosis in Indonesia persists and remains far from the WHO goal
of TB elimination by 2030. Dr. dr. Erlina Burhan, MSc., Sp.P(K), our founder and a respected
pulmonologist, believes that high-quality research, collaborative training, and implementation
activities involving various stakeholders in the field are essential to finding a solution to this
problem. As a result, TB Research & Training Center (TRTC) was established. When the COVID-
19 pandemic began in 2020, TRTC began conducting research on the disease. In 2022, TRTC
changed its name to Yayasan Riset dan Pelatihan Respirasi Indonesia (RPRI) as an established
legal entity and doing business as Saturate (Respiratory and Tuberculosis Research and
Training Center) to extend its scope beyond the TB sector and make a meaningful contribution to
respiratory services in Indonesia. At present, Saturate has more than 50 highly committed and
experienced pulmonologists and medical doctors and has conducted clinical trials on 21 drugs and
vaccines and 10 observational studies, with over 20,000 participants enrolled in 17 locations
throughout Indonesia. Our goal is to continue making contributions toward realizing Indonesia as a
nation free from TB and respiratory problems.

1.1.1. Company mission statement

Yayasan RPRI is a non-profit institution operating as a research and training center in the field of
pulmonology and respiratory medicine in Indonesia. Our mission is to identify the most painstaking
problem, generate the most novel solution, and implement the most strategic intervention for TB
and respiratory problems.

1.1.2. Accreditations
Yayasan RPRI is not in possession of any form of accreditation and is not currently undergoing any
accreditation procedure.

1.1.3. Organization structure

1.1.4. Geographical presence

 Yayasan RPRI is located on the 2nd floor of the Poli Paru building at Persahabatan General
Hospital, located on Jl. Persahabatan Raya No. 01 RT 016 RW 013 Pisangan Timur, Pulo Gadung,
East Jakarta 13230.

1.1.5. Declared audited financial statements

The audited financial statements of Yayasan RPRI are currently being processed, and we are
unable to provide the supporting documentation at this time. Nonetheless, we would like to assure
you that we aim to provide the said documentation no later than the end of April 2023.

1.2. Legal information

1.2.1. History of bankruptcy
Yayasan RPRI has not been subject to any court decision declaring bankruptcy under Indonesian
law. Our financial records and business dealings attest to our consistent fiscal responsibility and
stability. Our Ministry of Justice and Human Rights Registration Number is AHU-0005362.AH.01.04
with Tax Number 63.521.557.7-003.000.
1.2.2. Pending major lawsuits and litigations in excess of USD 100,000 at risk
Yayasan RPRI has no such cases pending or ongoing. We have maintained a clean legal record
and consistently operated in accordance with all relevant laws and regulations.
1.2.3. Pending criminal/civil lawsuits
Yayasan RPRI has maintained a clean legal record and has never been involved in any criminal or
civil lawsuits.

2. Experience and Reference Contact Information

2.1. Relevant contractual relationships
2.1.1. Relevant contractual projects
Yayasan RPRI has collaborated with the World Health Organization in conducting the Solidarity
Clinical Trial, an international clinical trial of adjunctive drugs for COVID-19 in hospital patients
receiving local standard of care. In addition to that, Yayasan RPRI partnered with the Indonesian
Society of Respirology to create a COVID-19 training module for healthcare providers, which was
supported by funding from the UNDP.

2.2. WHO Solidarity Trial

2.2.1. Project description, roles, and team members
The WHO Solidarity Trial is a large, global randomized control trial designed to determine
if a drug can effectively save lives in severe or critical COVID-19 cases. The trial originally
evaluated four repurposed drugs in addition to the local standard of care, with the objective
of comparing the outcomes of the local standard of care alone versus the local standard of
care combined with one of four alternative anti-viral agents. Co-sponsors of this study are
the National Ministry of Health and the World Health Organisation. Yayasan RPRI, a
research unit within Persahabatan Hospital, had been tasked with recruiting subjects,
ensuring protocol compliance, monitoring clinical data and source records, and
retaining study records for the trial in Persahabatan Hospital. The clinical team for this
project was composed of six individuals, one general practitioner, three pulmonologists, a
nurse, and a pharmacist. We successfully contributed to recruiting more than 50 patients
for this trial.
2.2.2. Status
Published.
2.2.3. Reason for relevance
Yayasan RPRI's participation in the WHO Solidarity Trial demonstrates our commitment to
global health research and collaboration, as it demonstrates Yayasan RPRI's capacity to
 engage in rigorous and collaborative research that can contribute to evidence-based public
health interventions. We are passionate to show our commitment to supporting the WHO's
global health goals. In addition, it is worth noting that two of our co-writers, Fathiyah
Isbandiyah and Riyadi Sutarto, had direct involvement in the WHO Solidarity Trial. Fathiyah
Isbandiyah served as a national investigator, while Riyadi Sutarto acted as a collaborator.
This experience serves as proof of their capabilities in working collaboratively within the
framework of the WHO.

2.3. UNDP – COVID-19 Module

2.2.4. Project description, roles, and team members
Yayasan RPRI partnered with the Indonesian Society of Respirology to create a COVID-
19 training module for healthcare providers. This initiative was funded by UNDP in 2021.
Fathiyah Isbaniah led the team (Erlina Burhan, Assica Permata, Azlina Darsaniya, and Aryo
Cahyo Byantoro) and spearheaded the development of the COVID-19 training module from
the ground up. Alongside this project, we also organized a training program for
pulmonologists, making use of the module that was created.
2.2.5. Status
Published.
2.2.6. Reason for relevance
Yayasan RPRI's experience in creating the COVID-19 module is relevant to this project is
through our expertise in developing modules and guidelines. Our knowledge in the field of
respirology will be directly applicable to the development of TB guidelines. The funding
provided by UNDP had given us the experience of working with international organizations,
their funding mechanisms, and reporting requirements. Also, our experience in
implementing the COVID-19 module, which included raising public awareness, training
healthcare professionals, and developing guidelines, had equipped us with the skills and
knowledge necessary to contribute effectively to the TB guideline development project. We
understand the importance of disseminating accurate information and providing proper
guidance to healthcare professionals to ensure the best possible care for patients.

3. Staffing Information
3.1. Number and geographical distribution of staff
3.1.1. Staff turnover rate for the past three years
a. 2020: 0%
b. 2021: 28.57%
c. 2022: 20.69%
3.1.2. Geographical distribution of staff, based on provinces
a. DKI Jakarta: 161 persons
b. West Sumatra: 49 persons
c. Banten: 17 persons
d. West Java: 38 persons

3.2. Staff dedicated to the project

3.2.1. Dr. dr. Erlina Burhan, SpP(K), MSc
a. Formal Education
Education Institution Graduation Year
PhD Faculty of Medicine University of 2012
Indonesia
 Consultant of Faculty of Medicine University of 2010
Respiratory Infection Indonesia
Pulmonologist Faculty of Medicine University of 2004
Indonesia
Master of Science in Heidelberg University 1995
Community Health
Medical Doctor Andalas University 1989

b. Organizational Experience
Organization & Position Year
StopTB Board Member, Private Sector Provides 2023–present
TB TV Founder and Host 2022–present
(https://www.youtube.com/@TuberculosisTV)
WHO consultant for TB Mission to Timor Leste 2022–present
Head of Indonesia Coalition of Professional Organization for 2020–present
Tuberculosis (KOPI TB)
WHO Guideline Development Group COVID-19 Treatment 2020–present
Head of COVID-19 Commando Team Persahabatan National 2020–present
Lung Hospital
Spokesman of COVID-19 Task Force Indonesian Medical 2020–present
Association (IMA)
Advisory Board Member Stop TB Partnership Indonesia 2018–present
Head of Advisory Board of The Indonesian Association 2017–present
Against Tuberculosis (PPTI)
Member of International Global Health Committee 2017–present
American Thoracic Society
Vice Chairman of TB Working Group Indonesia 2016–present
Principal Investigator and Steering Committee of National 2013–present
Institute of Allergy and Infectious Diseases (NIAID), Indonesia
Research Partnership on Infectious Disease (INA-RESPOND)
Country Director of American Thoracic Society (ATS) 2013–present
Methods in Epidemiologic, Clinical and Operations
Research (MECOR)
Government Member of Guideline Latent TB Infection 2013–present
Drug-Resistant TB Management for the National TB 2019–2021
Programme of Timor Leste
Board Member of Director International Union Tuberculosis 2018–2021
and Lung Diseases (IUTLD)
Implementing Organization Public Private Mix TB Indonesia 2018–2021
(Director)
Head of TB Assembly Asian Pacific Society of Respirology 2015–2021
(APSR)
Head of Indonesia Society of Respirology/PDPI Jakarta 2015–2021
Branch
Head of Pulmonary Infection Division, Department of 2013–2020
Pulmonology and Respiratory Medicine, Faculty of Medicine,
Universitas Indonesia
WHO Guideline Development Group on DRTB Treatment 2015–2018
 Member of The Regional Advisory Committee on MDR- 2013–2018
TB/rGLC, WHO SEARO

c. Work Experience
i. Staff of Department Pulmonology and Respiratory Medicine, University of
Indonesia (2004–present)
ii. Pulmonologist at Persahabatan Hospital, Jakarta (2004–present)
iii. Chairperson of Respiratory and Tuberculosis Research and Training Centre
(SATURATE) at Department of Pulmonology and Respiratory Medicine
Persahabatan Hospital (2020 – present)

3.2.2. Dr. dr. Fathiyah Isbaniah, Sp.P(K), MPd.Ked

a. Formal Education
Education Institution Graduation Year
PhD Faculty of Medicine University of 2021
Indonesia
Consultant of Faculty of Medicine University of 2021
Respiratory Infection Indonesia
Master of Medical Faculty of Medicine University of 2012
Education Indonesia
Pulmonologist Faculty of Medicine University of 2007
Indonesia
Medical Doctor Faculty of Medicine, the Christian 2000
University of Indonesia

b. Organizational Experience
Organization & Position Year
Member of the Indonesian Doctors Association (IDI) 2000–present
Member of the Indonesian Society of Respirology (PDPI) 2007–present
Member of American Thoracic Society (ATS) 2013–present
Deputy of General Secretary Indonesian Society of 2021–present
Respirology (PDPI)

c. Work Experience
i. Staff of Department Pulmonology and Respiratory Medicine, University of
Indonesia (2007–present)
ii. Pulmonologist at Persahabatan Hospital, Jakarta (2007–present)
iii. Head of Infection Division, Department of Pulmonology and Respiratory Medicine,
Persahabatan Hospital (2019–2022)

d. Related Publications
i. National Investigator in WHO Solidarity Trial (2021)
ii. Fathiyah Isbaniyah. Case Report: Culture Conversion in Bedaquiline Contain
Regiment of Pre-XDR and XDR TB Treatment in Persahabatan Hospital in
Indonesia. Am J RespirCrit Care Med 2017;195:A2104
iii. Fathiyah Isbaniah. Drug Resistant TB Treatment with Comorbidity-How To Deal
With Workshop Proceeding Book National Respiratory of Indonesia Society of
Respirology (PIK PDPI 2018).
 iv. Contributor in Tuberculosis Guidelines for Diagnosis and Management in
Indonesia (Indonesian Society of Respirology/PDPI). Jakarta, 2012. ISBN 979-
96614-7-1
v. Contributor in ISTC Tuberculosis Management Handbook with Private Doctor
Practice Strategies (Ministry of Health & IDI). Jakarta, 2012.
vi. Contributor in Guidelines for Prevention and Control of Tuberculosis Infection in
Hospitals (Ministry of Health & KNCV Indonesia). Jakarta, 2012
vii. Drafting Team in the Guidelines for Managing Community Pneumonia (Indonesian
Society of Respirology/PDPI). Jakarta, 2014. ISBN 978-602- 97308-3-8
viii. Contributor in the Guidelines for Service and Management of Tuberculosis
(Persahabatan Hospital–Ministry of Health). Jakarta, 2015
ix. Drafting Team in Handbook for Management of Latent TB Infection. Jakarta, 2016.
ISBN 978-602-97308-4-5
x. Drafting Team in Handbook on Prevention and Management of Health Impacts
Due to Forest Fire Smoke (Indonesian Society of Respirology/PDPI). Jakarta,
2019. ISBN 978-979-456-618-3
xi. Drafting Team in Handbook of COVID-19 Pneumonia. (Indonesian Society of
Respirology/PDPI). Jakarta, 2020. ISBN 978-623-92964-0-7
xii. Contributor in Technical Guidelines for the Management of Drug Resistant TB
(Ministry of Health). Jakarta, 2021

3.2.3. Dr. dr. Raden Rara Diah Handayani, Sp.P(K)

a. Formal Education
Education Institution Graduation Year
PhD Faculty of Medicine University of 2021
Indonesia
Consultant of Faculty of Medicine University of 2021
Respiratory Infection Indonesia
Pulmonologist Faculty of Medicine University of 2007
Indonesia
Medical Doctor Faculty of Medicine University of 2000
Indonesia

b. Organizational Experience
Organization & Position Year
Member of the Indonesian Doctors Association (IDI) 2000–present
Member of the Indonesian Society of Respirology (PDPI) 2007–present
Member of the American Thoracic Society (ATS) 2013–present

c. Work Experience
i. Staff of Department Pulmonology and Respiratory Medicine, University of
Indonesia (2010–present)
ii. Pulmonologist at Persahabatan Hospital, Jakarta (2010–present)
iii. Head of Education Coordination in Universitas Indonesia Hospital, Jakarta (2020–
present)

d. Related Publications
 i. Diah Handayani, Nurfanida Librianty, Priyanti Z. Soepandi. Association of
Previously Treated Tuberculosis Using Second Line TB Drugs with Conversion
Rate of Multi Drugs Resistance (MDR-TB) Patients in Indonesia.
https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-
conference.2016.193.1_MeetingAbstracts.A4482
ii. Nurfanida Librianty, Priyanti Z. Soepandi, Diah Handayani, Ahmad Fuady. Role
of Nutrition Status in Multidrug Resistant Tuberculosis (MDR-TB) Conversion.
https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-
conference.2016.193.1_MeetingAbstracts.A4483
iii. Erlina Burhan, Diah Handayani, Gatut Priyonugroho, Budi Haryanto, Ika
Fajarwati, Fachrul Tamrin. Diagnostic Discrepancy, A Drug Sensitive or MDR-TB:
Case Report. https://onlinelibrary.wiley.com/doi/epdf/10.1111/resp.13420_661
iv. Diah Handayani, Dwi Rendra Hadi, Erlina Burhan. Eligibility of Shorter Regimen
(STR) Among Multidrug Resistant Tuberculosis Patients in Persahabatan Hospital,
Indonesia. https://onlinelibrary.wiley.com/doi/epdf/10.1111/resp.13420_328
v. Ika Fajarwati, Diah Handayani, Erlina Burhan. Diabetes Mellitus Increase Risk of
Multidrug Resisitant Tuberculosis in Jakarta Indonesia.
https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-
conference.2019.199.1_MeetingAbstracts.A5153.
vi. Contributor in Handbook for Hospital Acquired Pneumonia (HAP) and Ventilator
Associated Pneumonia (VAP). Jakarta, 2018
vii. Drafting Team in Handbook of COVID-19 Pneumonia. (Indonesian Society of
Respirology/PDPI). Jakarta, 2020. ISBN 978-623-92964-0-7

3.2.4. Dr. dr. Heidy Agustin, Sp.P(K)

a. Formal Education
Education Institution Graduation Year
PhD Faculty of Medicine Hasanudin 2021
University, Makassar
Consultant of Faculty of Medicine University of 2021
Respiratory Infection Indonesia
Pulmonologist Faculty of Medicine University of 2008
Indonesia
Medical Doctor Faculty of Medicine, the Christian 2001
University of Indonesia

b. Organizational Experience
Organization & Position Year
Member of the Indonesian Doctors Association (IDI) 2001–present
Member of the Indonesian Society of Respirology (PDPI) 2008–present
Member of the Indonesian Oncology Association (POI) 1986–2005
Member of the Indonesian Bronchoscopy Association 1999–2004
(PERBRONKI)

c. Work Experience
i. Staff of Department Pulmonology and Respiratory Medicine, University of
Indonesia (2009–present)
ii. Pulmonologist at Persahabatan Hospital, Jakarta (2009–present)
 iii. Head of Training Installation & Respiration Simulation Persahabatan Hospital,
Jakarta (2020–present)

d. Related Publications
i. Heidy Agustin, Muhammad Nasrun Massi, Irawati Djahruddin, Agus Dwi Susanto,
Andi Asdul Islam, Muhammad Hatta, Agusalaim Bukhori, Nur Ahmad Thabri, Arif
Santoso, Ilhamjaya Patellogi Analysis of CD4 and CD8 expression in MDR TB
infection with DM: An expriental study in mice. Annals of Medicine and surgery
:68(2021) 102596
ii. Heidy Agustin, Muhammad Nasrum Massi, Irawati Djaharuddin, Agus Dwi
Susanto, Andi Asadul Islam, Mochammad Hatta, Agus salim Bukhari, Nur Ahmad
Tabri, Arif Santoso, Erlina Burhan, Fathiyah Isbaniyah, Farsida, Zulham Effendy.
Correlation expression toll-like receptor 4 with multidrug resistant tuberculosis in
diabetes mellitus condition. https://doi.org/10.1016/j.ijtb.2022.03.012
iii. Wiendo Syah Putra Yahya, Heidy Agustin, Faisal Yunus, Darmawan B Setyanto.
Tatalaksana Tuberkulosis Regimen Ganda (MDR-TB) pada anak. CDK-240/ vol.
43 no. 5 th. 2016
iv. Drafting Team in the Guidelines for Managing Community Pneumonia (Indonesian
Society of Respirology/PDPI). Jakarta, 2014. ISBN 978-602- 97308-3-8
v. Drafting Team in Handbook for Management of Latent TB Infection. Jakarta, 2016.
ISBN 978-602-97308-4-5
vi. Contributor in Technical Guidelines for the Treatment of Drug-Resistant TB with
Short-term Standard Guidelines at Drug-resistant TB Health Facilities. Jakarta,
2017
vii. Contributor in Handbook for Hospital Acquired Pneumonia (HAP) and Ventilator
Associated Pneumonia (VAP). Jakarta, 2018
viii. Drafting Team in Handbook of COVID-19 Pneumonia. (Indonesian Society of
Respirology/PDPI). Jakarta, 2020. ISBN 978-623-92964-0-7

3.2.5. dr. Riyadi Sutarto, SpP

a. Formal Education
Education Institution Graduation Year
Pulmonologist Faculty of Medicine University of 2019
Indonesia
Medical Doctor Faculty of Medicine University of 2009
Indonesia

b. Organizational Experience
Organization & Position Year
Member of the Indonesian Doctors Association (IDI) 2009–present
Member of the Indonesian Society of Respirology (PDPI) 2019–present

c. Work Experience
i. Staff of Department Pulmonology and Respiratory Medicine, University of
Indonesia (2020–present)
ii. Pulmonologist at Persahabatan Hospital, Jakarta (2020–present)

d. Related Publications
i. Collaborator from Indonesia in WHO Solidarity Trial
3.2.6. dr. Faiza Hatim, SpP
a. Formal Education
Education Institution Graduation Year
Pulmonologist Faculty of Medicine University of 2021
Indonesia
Medical Doctor Faculty of Medicine University of 2014
Indonesia

b. Organizational Experience
Organization & Position Year
Member of the Indonesian Doctors Association (IDI) 2014–present
Member of the Indonesian Society of Respirology (PDPI) 2021–present

c. Work Experience
i. Staff of Department Pulmonology and Respiratory Medicine, University of
Indonesia (2021–present)
ii. Pulmonologist at Persahabatan Hospital, Jakarta (2021–present)
iii. Research Assistant/Scientific Section for Indonesian Digestive Disease Week,
Gastroenterology Division, Department of Internal Medicine, FKUI/RSCM (2014-
2015)

d. Related Publications
i. Evidence Based Case Report: Ready-To-Use Therapeutic Food (RUTF) in
Chidren with Severe Malnutrition (2014)

3.2.7. dr. Nildza Kheirizzad

a. Formal Education
Education Institution Graduation Year
Medical Doctor Faculty of Medicine University of 2023
Indonesia

b. Work Experience
i. Research Assistant at Respiratory and Tuberculosis Research and Training
Center (SATURATE)–Persahabatan Hospital, Jakarta (2023–present)

3.2.8. Staffing
a. Team Leader: Dr. dr. Erlina Burhan, SpP(K), MSc
b. Co-writers:
i. Dr. dr. Fathiyah Isbaniah, Sp.P(K), MPd.Ked (TB-DM)
ii. Dr. dr. Raden Rara Diah Handayani, Sp.P(K) (TB-Other comorbidities)
iii. Dr. dr. Heidy Agustin, Sp.P(K) (TB-HIV)
iv. dr. Riyadi Sutarto, SpP (TB-Tobacco)
v. dr. Faiza Hatim, SpP (TB-Nutrition)
c. Administrative Staff: dr. Nildza Kheirizzad

3.2.9. Time dedicated to the project

Our team is fully committed to dedicating 50% of our Full-Time Equivalent (FTE) towards
the project. Our team comprises skilled professionals with diverse experiences, and we are
confident that our collective expertise will enable us to deliver quality work that meets or
 exceeds the expectations. We are committed to regular communication and updates
throughout the project's lifecycle to ensure that our efforts remain aligned with the
expectations.

3.2.10. Contingency plans in the event of a vacancy

To ensure that the project runs seamlessly even in the event of a staff vacancy, our
contingency plan consists of several steps. Firstly, we will identify the critical role(s) that
require immediate attention, followed by creating a list of potential replacement personnel
who have the necessary qualifications to take over. To prepare these backup staff
members, we will initiate a cross-training program to familiarize them with the project's
requirements and procedures. Additionally, we will maintain updated documentation of the
workflows, processes, and procedures, which will be accessible to all team members,
including the backup staff. We will also organize regular team meetings to promote
transparent communication and keep everyone informed of the project's progress. These
meetings will take place as scheduled, even if some members are absent. To ensure
transparency and timely decision-making, we will provide progress reports to stakeholders
regularly.